Many patients on GLP‑1 therapy describe their cravings as quieter, their urges to snack reduced, and their minds less consumed by food. This shift, often described as a reduction in “food noise,” reflects significant physiological changes triggered by GLP‑1 medications. As more clinicians prescribe these therapies, it’s vital to understand …

In clinical practice, patients with both type 2 diabetes and heart failure with preserved ejection fraction (HFpEF) often present with overlapping symptoms and complex care needs. The evolving landscape of cardiometabolic treatment has brought new attention to GLP‑1 HFpEF diabetes management, especially as recent evidence suggests that glucagon-like peptide‑1 receptor …

The arrival of oral GLP‑1 therapy for type 2 diabetes marks a pivotal shift in diabetes care. Traditionally available only as injections, GLP‑1 receptor agonists have shown impressive results in lowering blood glucose, aiding in weight loss, and protecting the heart. Now, oral versions like semaglutide are removing barriers for …

With the release of the ADA 2026 diabetes sleep guidelines, the American Diabetes Association has officially elevated sleep and circadian rhythm health to core pillars of diabetes care—right alongside nutrition, physical activity, and medication. These new standards mark a significant shift toward more holistic and behavioral-focused approaches to managing diabetes. …

The rising interest in GLP‑1 MASLD MASH treatment has transformed how clinicians view metabolic therapies for patients with type 2 diabetes and obesity. While GLP‑1 receptor agonists have long been recognized for their glucose-lowering and weight-loss effects, they now offer potential for improving liver outcomes, especially in individuals with metabolic …

Managing type 2 diabetes in people with advanced chronic kidney disease (CKD) and end-stage kidney disease (ESKD) on dialysis presents unique clinical challenges. With the 2026 Standards of Care increasingly shifting the focus toward cardio-renal outcomes, many clinicians are asking: how far can we go safely with GLP‑1 receptor agonists …

With diabetes technology evolving rapidly, clinicians face more choices than ever before. From continuous glucose monitors (CGMs) to insulin pumps and patch devices, today’s tools can transform diabetes care—but only when matched to the right patient. This article provides a comprehensive diabetes technology comparison, helping you understand each option’s features, …

GLP‑1 receptor agonists have changed the way we treat type 2 diabetes and obesity, offering powerful glucose-lowering effects and sustained weight loss. But as more patients stay on these medications for years—not just months—questions around GLP‑1 long‑term safety have become essential to address. From gastrointestinal discomfort to gallbladder risks and …

The GLP‑1 mechanism of action is more than a tool for lowering glucose—it’s a central player in a complex system influencing body weight, cardiovascular outcomes, liver health, and possibly even brain function. As GLP‑1 receptor agonists become more widely prescribed, understanding how this pathway works helps clinicians better tailor treatments …

Imagine reducing your patients’ insulin injections from 365 a year to just 52. That’s the promise of once‑weekly insulin — a next-generation option designed to simplify treatment, enhance adherence, and improve patient outcomes. While this innovation is gaining traction, many healthcare providers still have questions about when and how to …